Cimaglermin acts as a growth factor for the heart, helping it repair itself following injury, Lenihan said

Heart failure patients have weakened hearts, but researchers say an experimental drug used for the first time in humans may repair heart cells and improve heart function.

사다리밸런스 작업 / 해와달밸런스 작업 / 365일 전국 당일작업 / 고수익보장 / 사벤져스 / 카톡 SAVENGERSAccording to the results of a small phase 1 trial, a single intravenous infusion of the drug cimaglermin was safe and, at high doses, improved heart function for at least three months.

“Right now we have many therapies that we use for heart failure, and these patients [in the study] were on all of those therapies and still had significant heart dysfunction,” said lead researcher Dr. Daniel Lenihan. He’s a professor of medicine and director of Vanderbilt University’s heart clinical research program in Nashville.

People with heart failure often take a combination of drugs, Lenihan said. These include medications to lower blood pressure and diuretics to help remove excess fluid that builds up as a result of the heart’s labored pumping ability. In addition, some people have implanted defibrillators or pacemakers.

Even with all these options, the death rate among these patients is “unacceptably high,” Lenihan said.

Heart failure, a condition where the heart can’t pump enough blood to meet the body’s needs, is among the leading causes of death worldwide. A significant number of heart failure patients don’t respond well to current treatments, particularly those patients whose left lower heart chamber, which pumps blood into the arteries, is weak, Lenihan said.

Cimaglermin acts as a growth factor for the heart, helping it repair itself following injury, Lenihan said. Specifically, it binds to the HER2 and HER4 receptors on the surface of heart cells that are important for cellular repair and survival, he explained.

Researchers have tried using stem cells to repair heart muscle in much the same way, he said, but these efforts have not been effective. “You don’t see any sustained effect,” he added.

A phase 1 trial like this one is designed to see if a new drug is safe, not to test its effectiveness. Before cimaglermin could be used to treat patients, it must prove its worth in a series of progressively larger and challenging trials and then be approved by the U.S. Food and Drug Administration. The process can take several years. Based on these preliminary findings, larger trials are being planned, Lenihan said.

“This drug, although still in an experimental phase, might be an important way to improve heart function in patients with heart failure,” he said.

For the study, Lenihan and his colleagues randomly assigned 40 patients to get an infusion of cimaglermin or a placebo.

Compared with patients who received a placebo, patients given a high dose of cimaglermin had a sustained increase in the heart’s ability to pump blood. The improvement lasted 90 days, with the maximum increase in heart function reached in 28 days, the researchers found.

The most common side effects were headache and nausea directly after receiving the drug. One patient who received the highest dose of cimaglermin developed abnormal liver function, which cleared up over a two-week period, Lenihan said.

The study was funded by Acorda Therapeutics, the maker of cimaglermin, and the report was published online Dec. 26 in the journal JACC: Basic to Translational Science.

Dr. Nanette Bishopric is a professor of medicine at the University of Miami Miller School of Medicine and the author of an accompanying journal editorial. “There haven’t been breakthrough treatments for heart failure for a long time,” she said.

Cimaglermin, however, may be such a drug, 배터리게임 she said. “It’s a remarkable thing that you could give a drug once and have it affect heart function three months later — it’s really extraordinary,” she said.

Every drug currently used to treat heart failure has to be given daily or several times a day to get it to work, Bishopric said. “And when you stop taking it, it stops working,” she said.

Despite the encouraging results of this first trial, a lot more testing will be needed before cimaglermin can be considered a standard treatment for heart failure, Bishopric said.

“These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,” she noted.

Related Posts

Rescued migrants escaping North Africa expected to arrive Sunday in Spain
According to WXPI in Pittsburgh, Pa., police say that Acosta was not supposed to be at the Pittsburgh Convention Center during the “American Idol” auditions last week. When asked to vacate the premises, the report states she “refused to leave and became combative.” Acosta is being charged with trespassing and resisting arrest. Acosta admitted to ABC affiliate WTAE in Pittsburgh that she has been traveling to various cities and attempting to audition for the show, and it’s her dream to make it as a singer. “I have a stack this big of airline tickets,” Acosta said to WTAE. “I’ve been to California everywhere. I’ve been to Texas. I’ve been to Arizona. St. Louis. I’ve been to Denver, Colo., here, New York — I can keep going.” The “American Idol” hopeful told both Pittsburgh stations the police report is wrong. She admitted to being questioned by security at the audition, but says one member of the staff told her she was not trespassing and went upstairs to clear the matter. According to Acosta, she was arrested after that person left. She also strongly denies the claim in the police report that she said, “I’m not leaving, this is my dream, my life is ruined.” “I said, ‘I wasted almost $10,000 this summer traveling.’ I’m pretty much broke until I work this weekend,” she told WTAE. “I think it’s going to be better anyways. Christina Aguilera (a ‘Voice’ judge) is from here, so I’d like to compare myself to her, and I love her,” Acosta said to WTAE.
Scorsese and Olivia Harrison,  widow of the late Beatle, were on hand at this year’s New York Film Festival for the red-carpet premiere of their new documentary, “George Harrison: Living in the Material World.”  The two-part made-for-TV film is  a comprehensive look at the life and spiritual quest for enlightenment of the legendary musician, who died in 2001 after battling lung cancer

No comments

Leave a Reply

Your email address will not be published. Required fields are marked *